Toon Dictus

Toon’s representative matters include advising:

Sustainability/ESG Regulatory

• Global platforms on compliance with emerging EU sustainability and global ESG regulatory frameworks, including regarding circularity, eco-design, deforestation, climate change, and energy transition
• International banks, funds, and corporates on sustainability reporting under the EU CSRD and other global climate or ESG reporting frameworks
• States and corporate undertakings on developments regarding the EU sustainability Omnibus initiative and corporate sustainability frameworks
• A multinational conglomerate in the technology and FMCG sectors in the establishment of human rights and environmental value chain due diligence procedures in the context of emerging EU and global regulatory frameworks*
• A global energy major on regulatory and antitrust/competition regulatory aspects of sustainability agreements and initiatives*

Transactional

• Energy Capital Partners (EPC) and Centrica on the environmental aspects of their acquisition from National Grid of Grain LNG, Europe’s largest liquefied natural gas (LNG) terminal
• Honeywell International on the environmental and ESG aspects of its acquisition of Johnson Matthey's Catalyst Technologies business, a provider of catalyst manufacturing and licensing of process technology
• NorthC and DWS Pan-European Infrastructure Fund IV on ESG aspects of its acquisition from Colt Technology Services of multiple data centers across Europe
• 65 Equity Partners and Inflexion on EHS aspects of their investment in Kee Safety, a global leader in safety systems and solutions
• TPG Rise Climate in certain sustainability aspects of its acquisition of a stake in SICIT, an Italy-based circular-economy oriented producer of  biostimulants
• American Express in its sale of Accertify, a technology company provider prevention solutions technology, to Accel-KKR*
• Artemis in its acquisition of a majority stake in CAA, an entertainment, media, and sports enterprise*
• AbbVie in its acquisitions of Syndesi Therapeutics, a biopharmaceutical company, and its novel “option to acquire” the equity securities of iStar Medical SA, a medical technology company*

*Matter handled prior to joining Latham